TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26257796

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic exercise (Control)
Number of subjects: 40
Study: 23279709

Group type: EXPERIMENTAL
Intervention: Moist cool air device (MCAD) exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without MCAD)
Number of subjects: 20
Study: 21554520

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18813028

Group type: EXPERIMENTAL
Intervention: ORS+LGG powder containing 10(10) CFU (group B)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: ORS+LGG powder containing 10(12) CFU (group C)
Number of subjects: 559

Group type: COMPARATOR
Intervention: ORS (group A/control)
Number of subjects: 559
Study: 17542944

Group type: EXPERIMENTAL
Intervention: Melatonin (1.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15363007

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (800 micro g budesonide) for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11822764

Group type: EXPERIMENTAL
Intervention: etoposide
Number of subjects: 690

Group type: COMPARATOR
Intervention: no etoposide
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: high-dose therapy
Number of subjects: 690
Study: 9516059

Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg) over 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study: 8071053

Group type: EXPERIMENTAL
Intervention: Iopromide (370 mg I/mL)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Iopamidol (370 mg I/mL)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Iohexol (350 mg I/mL)
Number of subjects: 161
Study: 3127845

Group type: EXPERIMENTAL
Intervention: Amitriptyline at low plasma drug levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amitriptyline at medium plasma drug levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amitriptyline at high plasma drug levels
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment in patients aged 25 to 65 years
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment in patients aged 65 to 80 years
Number of subjects: 74
Study: 29610026

Group type: EXPERIMENTAL
Intervention: Accelerated corneal crosslinking (CXL) using higher fluence (7.2 J/cm2) and treatment time (4 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Accelerated corneal crosslinking (CXL)
Number of subjects: 20
Study: 27716157

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (6.7 ml)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (10 ml)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (20 ml)
Number of subjects: 99

Group type: COMPARATOR
Intervention: All groups (0.75%, 0.5%, 0.25%)
Number of subjects: 99
Study: 24724093

Group type: EXPERIMENTAL
Intervention: Comorbid PTSD/mTBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (OEF/OIF Veterans with no history of mTBI and/or PTSD)
Number of subjects: 0
Study: 24071759

Group type: EXPERIMENTAL
Intervention: Web-based self-management program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 65
Study: 20575271

Group type: EXPERIMENTAL
Intervention: Hib vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hi culture positive
Number of subjects: 0
Study: 17568397

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cocaine (0, 12, 25, and 50 mg)
Number of subjects: 8
Study: 17646493

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 microg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.5 microg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14692723

Group type: EXPERIMENTAL
Intervention: Kava special extract WS 1490 (150 mg/d, 3 x 1 capsule of 50 mg/d)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Kava special extract WS 1490
Number of subjects: 141
Study: 10981439

Group type: EXPERIMENTAL
Intervention: Pressure Support (PS) ventilation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Amplified Spontaneous Pattern (ASP) ventilation
Number of subjects: 18
Study: 9062416

Group type: EXPERIMENTAL
Intervention: Follow-up visit
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Follow-up preference
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 212
Study: 8103473

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intraperitoneal insemination (IPI)
Number of subjects: 54
Study: 3769570

Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism
Number of subjects: 3
Study: 31571341

Group type: EXPERIMENTAL
Intervention: Full exposure to crowdsourced images and videos intervention
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Partial exposure to crowdsourced images and videos intervention
Number of subjects: 470

Group type: COMPARATOR
Intervention: No exposure to intervention
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Not having a recent doctor's visit
Number of subjects: 470
Study: 29275505

Group type: EXPERIMENTAL
Intervention: 3RP‐NF (mind-body program)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (attention placebo)
Number of subjects: 63
Study: 26756977

Group type: EXPERIMENTAL
Intervention: Sildenafil-Ambrisentan (S+A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil-Bosentan (S+B)
Number of subjects: 0
Study: 24980440

Group type: EXPERIMENTAL
Intervention: Integrative Treatment (IT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Therapeutic Acupuncture (TA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 120
Study: 21998264

Group type: EXPERIMENTAL
Intervention: Strength training (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endurance training (n = 13)
Number of subjects: 25
Study: 20553591

Group type: EXPERIMENTAL
Intervention: Anterior discectomy only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior discectomy with interbody fusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior discectomy with disc prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18279823

Group type: EXPERIMENTAL
Intervention: Mentoring by experienced chairs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no mentoring)
Number of subjects: 27
Study: 15735200

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12927999

Group type: EXPERIMENTAL
Intervention: Newer cytotoxic agents (gemcitabine, PEG-liposomal doxorubicin, topotecan) in combination with platinum-based therapy
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Standard platinum/taxane therapy (carboplatin and paclitaxel)
Number of subjects: 3400
Study: 11261633

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9251377

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1622957

Group type: EXPERIMENTAL
Intervention: Topical application of 5% eutectic mixture of lignocaine and prilocaine (EMLA) (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (similar emulsion containing no local anaesthetic) (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (infiltration anaesthesia with lignocaine if requested) (n = 15)
Number of subjects: 45
Study: 6381775

Group type: EXPERIMENTAL
Intervention: Moxalactam and ampicillin sodium therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Amikacin sulfate and ampicillin therapy
Number of subjects: 63
Study: 30458757

Group type: EXPERIMENTAL
Intervention: Delay of Event (DoE) of 18 months
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Delay of Event (DoE) of 6 months
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Delay of Event (DoE) of 1 month
Number of subjects: 1041
Study: 26686567

Group type: EXPERIMENTAL
Intervention: Lomitapide (10-60 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24794720

Group type: EXPERIMENTAL
Intervention: 0.5-mg nitroglycerin gel (1 mL) applied vaginally 30 min prior to IUD placement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Identical placebo gel applied vaginally 30 min prior to IUD placement
Number of subjects: 24
Study: 22506466

Group type: EXPERIMENTAL
Intervention: Observation group (MCL rupture)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no MCL rupture)
Number of subjects: 127
Study: 20350942

Group type: EXPERIMENTAL
Intervention: vicriviroc-ritonavir (30 and 100 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: vicriviroc-ritonavir (150 and 100 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: ritonavir (100 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: vicriviroc (200, 250, or 300 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: vicriviroc (150, 200, or 250 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 230
Study: 18581699

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 16227990

Group type: EXPERIMENTAL
Intervention: Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early T-cell infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination vaccine therapy and adoptive T-cell transfer
Number of subjects: 0
Study: 11927062

Group type: EXPERIMENTAL
Intervention: 1000 gauss magnet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo metal disk
Number of subjects: 30
Study: 9456253

Group type: EXPERIMENTAL
Intervention: Indinavir in combination with nucleoside analogue reverse transcriptase inhibitors
Number of subjects: 14
Study: 7610506

Group type: EXPERIMENTAL
Intervention: LHRH analogues treatment
Number of subjects: 29
Study: 2540581

Group type: EXPERIMENTAL
Intervention: Lonidamine (up to 1050 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: MVP (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 25
Study: 779590

Group type: EXPERIMENTAL
Intervention: Alprenolol (400 mg daily, increased to 533 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg daily, increased to 25 mg)
Number of subjects: 22
Study: 29535447

Group type: EXPERIMENTAL
Intervention: Grand Theft Auto V (violent video game)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: The Sims 3 (non-violent video game)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No game (passive control group)
Number of subjects: 0
Study: 28802804

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) delivered to the left DLPFC for a single 20-minute session
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44
Study: 25777588

Group type: EXPERIMENTAL
Intervention: SCT-based SHED-IT WLM Program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-help control group
Number of subjects: 92
Study: 23295101

Group type: EXPERIMENTAL
Intervention: Contrast enhanced transesophageal echocardiography (TEE)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Native transesophageal echocardiography (TEE)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (native TEE)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Contrast enhanced TEE
Number of subjects: 180
Study: 21671884

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) administered twice daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) administered twice daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) administered alone for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (325 mg single dose)
Number of subjects: 0
Study: 19920048

Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 microg/kg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 16954734

Group type: EXPERIMENTAL
Intervention: Enfuvirtide discontinued
Number of subjects: 18

Group type: COMPARATOR
Intervention: Enfuvirtide continued
Number of subjects: 18
Study: 9918280

Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Other drugs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Equipment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Other interventions
Number of subjects: 41
Study: 8752811

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study: 1671361

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.5 microgram/kg per minute)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6859836

Group type: EXPERIMENTAL
Intervention: Amantadine (100 or 200 mg daily for 5 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Aspirin (3.25 g daily for 5 days)
Number of subjects: 47
Study: 31912226

Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise (RE) at 50% of maximal voluntary contraction for 20 seconds
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise (RE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Valsalva manoeuvre (VM)
Number of subjects: 11
Study: 30944112

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 294

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 294
Study: 30072404

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 22379

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones
Number of subjects: 22379
Study: 26432693

Group type: EXPERIMENTAL
Intervention: Evidence-based depression care management for 2 years, including psychotherapy and medication management
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Nondepressed patients in intervention and usual care practices
Number of subjects: 1204
Study: 22020083

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher parasitemias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anemic children
Number of subjects: 0
Study: 22708640

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metoprolol succinate (50-100 mg daily)
Number of subjects: 80
Study: 20056929

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation for acute stroke trials
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Local presentation to the hub
Number of subjects: 28
Study: 18051491

Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol as a single intravenous preemptive dose
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16268007

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle group (HL) - engaged in exercise for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 12161723

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 421

Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 421
Study: 10554363

Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Open herniorrhaphy (OH)
Number of subjects: 123
Study: 7759701

Group type: EXPERIMENTAL
Intervention: Metoprolol (Controlled Release, 200 mg once daily)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Nifedipine (Retard, 20 mg twice daily)
Number of subjects: 280
Study: 2261152

Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mirror tracing
Number of subjects: 40
Study: 31130280

Group type: EXPERIMENTAL
Intervention: GDF-15 measurement
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Fried score
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Charlson index
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 208
Study: 29486881

Group type: EXPERIMENTAL
Intervention: Topical regenerative agent
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 26921460

Group type: EXPERIMENTAL
Intervention: Adjunctive antimicrobial photodynamic therapy (aPDT) with indocyanine green (ICG) + SRP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 50
Study: 25568553

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4 (HES)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (1000 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (1000 ml)
Number of subjects: 90
Study: 22233204

Group type: EXPERIMENTAL
Intervention: Tofacitinib (30 mg twice daily for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (2 mg single dose)
Number of subjects: 0
Study: 20434823

Group type: EXPERIMENTAL
Intervention: BIG Bone Injection Gun
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 40
Study: 18090299

Group type: EXPERIMENTAL
Intervention: NRTI-based HAART
Number of subjects: 650
Study: 16120067

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily for 5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg once daily for 6 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12131606

Group type: EXPERIMENTAL
Intervention: Infliximab 5, 10, or 20 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9927022

Group type: EXPERIMENTAL
Intervention: Physical training (4 months, 5 days/week, 40 minutes/session, mean HR 157 beats/min, EE 925±201 kJ)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 74
Study: 7779149

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam (2 x 20 mg on days 1 and 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2186832

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 87082

Group type: EXPERIMENTAL
Intervention: Oral retinoid (Ro 10‐9359) and UVB radiation (Selective Ultraviolet Phototherapy=SUP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Radiation therapy only (control group)
Number of subjects: 23
Study: 30187593

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) trial rental subsidies redeemable in low-poverty neighborhoods plus housing counseling
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Unrestricted Section 8 rental subsidies
Number of subjects: 3537

Group type: COMPARATOR
Intervention: Public housing control
Number of subjects: 3537

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) trial
Number of subjects: 3537
Study: 29254115

Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 31
Study: 25828427

Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motor training (both groups)
Number of subjects: 40
Study: 23333292

Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 12 weeks
Number of subjects: 360
Study: 22153395

Group type: COMPARATOR
Intervention: Conventional hang-back technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anchored hang-back technique
Number of subjects: 60
Study: 19435390

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpharmacologic methods or other medications
Number of subjects: 0
Study: 17349643

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 136
Study: 14722734

Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (100 mg/m2 and 50 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (130 mg/m2 and 50 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ZD9331 in combination with cisplatin (130 mg/m2 and 75 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination therapy (ZD9331 and cisplatin)
Number of subjects: 16
Study: 11289395

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2271
Study: 9747868

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study: 7886750

Group type: EXPERIMENTAL
Intervention: Alphamethrin-impregnated bed nets
Number of subjects: 0